1. Mouse islets were used to define the characteristics and study the mechanisms of the stimulation of insulin release by compound carbamoyl]methyl] benzoic acid, a substituted benzoic acid with an asymmetric carbon atom. 2. At a non-stimulatory concentration of glucose (3 mM), (-)-AZ-DF 265 reversibly inhibited 86Rb efflux from islet cells, depolarized the beta-cell membrane, induced electrical activity, stimulated 45Ca efflux, and triggered insulin release. Maximum inhibition of 86Rb efflux occurred at 0.03 microM (-)-AZ-DF 265, whereas the threshold concentration for stimulation of release was 0.1 microM. Omission of extracellular Ca2+ abolished all effects of the drug but the inhibition of 86Rb efflux. 3. At a stimulatory concentration of glucose (10 mM), (-)-AZ-DF 265 reversibly increased 86Rb efflux, potentiated electrical activity, augmented 45Ca efflux, and increased insulin release. Maximum stimulation of 86Rb efflux and in...
Introduction
Measurements of ionic fluxes in islet cells with radioactive tracers (Henquin, 1980; Hellman, 1981; Henquin & Meissner, 1982; Matthews & Shotton, 1984a) , recordings of the 13-cell membrane potential with microelectrodes (Matthews et al., 1973; Henquin & Meissner, 1982) , characterization of single channel properties with the patch-clamp technique (Sturgess et al., 1985; Trube et al., 1986) , and estimations of cytoplasmic free Ca2" concentration with a fluorescent dye (Abrahamsson et al., 1985) have concurred to elucidate the mechanisms by which tolbutamide, the prototype of sulphonylureas of the first generation, increases insulin release. There is now wide agreement that the stimulation of P-cells by tolbutamide involves the following steps: by blocking ATP-dependent K+ channels, tolbutamide decreases K+ permeability of the P-cell membrane; this causes a depolarization that 'Author for correspondence at University of Louvain, Brussels.
activates voltage-dependent Ca2" channels; the ensuing Ca2" influx brings about a rise in cytoplasmic free Ca2" that ultimately triggers exocytosis of insulin granules. It is also believed that the same sequence of events underlies the action of the more potent sulphonylureas of the second generation such as glibenclamide or gliquidone (Matthews & Shotton, 1984a; Ferrer et al., 1984; Garrino et al., 1985; . However, the molecular mechanisms ofthe interaction of sulphonylureas with their target (K+ channels) are still unknown.
Two recent studies demonstrated that benzoic acid derivatives corresponding to the non-sulphonylurea moieties of glibenclamide and gliquidone stimulate Pcells by the same mechanism as the parent molecules (Garrino et al., 1985; . It is evident from these observations that the interaction with K+ channels does not require a sulphonylurea group. However, the relatively low efficacy of these derivatives (100 to 200 times less potent than the parent molecules) does not preclude the possibility that such a sulphonylurea group is the optimal chemical structure for blocking K+ channels in P-cells.
In the present study we show that compound (Figure 1 ), 4-[[N-(o-phenyl- .1/ CH-NH-CO-CH2 COOH Figure 1 Structural formula of AZ-DF 265.
Methods
All experiments were performed with islets of fed female NMRI mice (25-30 g), killed by decapitation.
For electrophysiological experiments, a piece of pancreas was fixed in a small perifusion chamber, and the membrane potential of single P-cells was continuously recorded with microelectrodes (Meissner & Schmelz, 1974) . P-Cells were identified by the typical electrical activity that they display in the presence of 10-15 mM glucose (Matthews et al., 1973; Meissner, 1976) . For all other experiments, islets were isolated after collagenase digestion of the pancreas. The techniques and the dynamic system of perifusion used to monitor the efflux of 45Ca or 86Rb (used as tracer for K) from preloaded islets have been described (Henquin, 1979 (Henquin & Lambert, 1975 (Figure 2 ). The inhibition of 86Rb efflux occurred rapidly, but was progressive and stabilized 8-O min after addition of the drug, when 45Ca efflux and insulin release started to increase. Removal of (-)-AZ-DF 265 from the medium was followed by a delayed reversal of the stimulation of 4"Ca efflux and insulin release, that was accompanied by a transient further decrease in 'Rb efflux.
The inhibition of 86Rb efflux was faster and more pronounced when the medium did not contain Ca2".
Its reversal was also delayed but was more complete than in the presence ofextracellular Ca2". Neither 45Ca efflux, nor insulin release was affected by (-)-AZ-DF 265 in the absence of Ca2" (Figure 2 ).
When the islets were perifused with a medium containing 3mM glucose and 2.5mM Ca2", 0.03 LM (-)-AZ-DF 265 slowly depolarized the P-cell membrane and induced electrical activity ( Figure 3a ). This activity consisted of small amplitude spikes when the cell membrane was still depolarizing and of much larger spikes when the membrane potential had stabilized at a plateau. After removal of the drug, the In the presence of 10 mM glucose and 2.5 mM Ca2", its maximum effect at 0.3 JtM. The changes in 86Rb efflux and insulin release induced by (+ )-AZ-DF 265 followed the same timecourse as those induced by an equipotent concentration of (-)-AZ-DF 265. The concentration of each enantiomer also had little influence on that timecourse, but the onset of the effect became faster as the concentration was raised. For instance, in the presence of 3 mM glucose, the first significant increase above basal insulin release occurred after 12 min and 6 min with 0.1 M and 1 gM (-)-AZ-DF 265, respectively. However, the progression of the response, without an initial peak of secretion, persisted. The other significant difference was that the reversal of the effects became slower and less complete as higher concentrations of the drug were used.
Discussion
In a recent communication (Grell et al., 1986) it was reported that compound AZ-DF 265 causes hypoglycaemia in the rat, with an efficacy comparable with that of glibenclamide, the most powerful hypoglycaemic sulphonylurea currently used in clinical practice. The present study demonstrates that AZ-DF 265 is indeed a very potent stimulator of insulin release in vitro. A direct action on pancreatic ,-cells may thus account for its hypoglycaemic properties.
Comparison with one of our previous studies (Garrino et al., 1985) indicates that, in the presence of 3 mM glucose, the effects of 0.1 ,IM glibenclamide on 'Rb efflux and insulin release were similar to those of efflux and on insulin release from mouse islets perifused with a medium containing a stimulatory concentration of glucose (G 1O mM). The experiments were performed in the presence of 2.5 mM Ca2" (-) presence of 10 mm glucose, the effects of 0.02 ILM glibenclamide were similar to those of 0.01-0.03 1IM (-)-AZ-DF 265. Glibenclamide and (-)-AZ-DF 265 thus appear to have roughly the same potency in our in vitro system. This conclusion is unlikely to be biased by important differences in the proportion of free drug in the medium, since AZ-DF 265 is as extensively bound to plasma proteins as glibenclamide (Crooks & Brown, 1974; A. Greischel, personal communication) . Glibenclamide and (-)-AZ-DF 265 not only appear to be equipotent, but their respective effects on ionic fluxes, P-cell membrane potential and insulin release display a fairly similar, progressive time-course (Ostenson et al., 1983; Ferrer et al., 1984; Pace, 1984; Garrino et al., 1985) . It should be pointed out that whenever glibenclamide was shown to exert rapid effects on P-cells (Meissner & Atwater, 1976; Ostenson et al., 1983; Matthews & Shotton, 1984a; Ferrer et al., 1984; Pace, 1984) , the drug was used at high concentrations (1-1I00 gM), that considerably exceed the levels ever reached in the plasma of treated patients (Rupp et al., 1972 ). An important difference exists, however, between AZ-DF 265 and glibenclamide: all effects of AZ-DF 265 were at least partially reversible, whereas the effects of glibenclamide are practically irreversible within the time studied (Meissner & Atwater, 1976; Ostenson et al., 1983; Matthews & Shotton, 1984a , Ferrer et al., 1984 , even when the sulphonylurea is used at low concentrations, equipotent to those of(-)-AZ-DF 265 (Garrino et al., 1985) .
The progressiveness of the changes recorded upon addition and withdrawal of glibenclamide or AZ-DF 265 contrasts with the rapidity of the changes brought about, under similar conditions, by a less potent sulphonylurea such as tolbutamide (Henquin, 1980; Henquin & Meissner, 1982; Matthews & Shotton, 1984a ), or by a benzoic acid derivative such as compound HB 699, which contains the non-sulphonylurea moiety of glibenclamide (Garrino et al., 1985) . It is possible that the high potency of drugs active at nanomolar concentrations is due to their progressive accumulation in the P-cell membrane (Deleers & Malaisse, 1984; Gylfe et al., 1984) , thereby submitting their target (K+ channels) to the influence of a concentration substantially higher than that of the medium. Further structure-activity studies will be necessary to establish whether an increase in drug potency is inevitably associated with a decrease in the rapidity of its effects and of their reversal.
The changes in ionic fluxes and P-cell membrane potential brought about by AZ-DF 265 were qualitatively similar to those produced by hypoglycaemic sulphonylureas or by other benzoic acid derivatives (Henquin, 1980; Hellman, 1981; Henquin & Meissner, 1982; Matthews & Shotton, 1984a; Ferrer et al., 1984; Pace, 1984; Garrino et al., 1985; . These analogies make it unnecessary to discuss again these changes in detail. They permit one to conclude that AZ-DF 265 depolarizes the P-cell membrane by decreasing its permeability to K+ and that this depolarization leads to activation of voltagedependent Ca2" channels with subsequent influx of c2+.
Ca'
However, two apparently paradoxical observations deserve some comment. The inhibition of 'Rb efflux produced by (-)-AZ-DF 265 at low glucose was larger in the absence than in the presence of Ca2', and was not directly dose-dependent in the presence of Ca2+. It was maximum at the concentrationjust below that starting to stimulate insulin release. A similar phenomenon has been observed with sulphonylureas and other benzoic acid derivatives (Henquin & Meissner, 1982; Matthews & Shotton, 1984a; Garrino et al., 1985; . It can be ascribed to activation, by incoming Ca2`and the greater depolarization of the membrane (Henquin, 1979; Matthews & Shotton, 1984b; Trube et al., 1986) , of K+ channels not blocked by AZ-DF 265. These are probably the voltage-and Ca2+-activated K+ channels identified in islet cells (Cook et al., 1984; Findlay et al., 1985) , but the intervention of Ca2`-activated, non-selective cation channels (Sturgess et al., 1986 ) is also possible. The same explanation holds true for the small acceleration of 86Rb efflux caused by (-)-AZ-DF 265 in the presence of 10 mM glucose. Conversely, the further decrease in 'Rb efflux occurring when (-)-AZ-DF 265 was withdrawn from a medium containing 3 mM glucose and 2.5 mM Ca2`may reflect suppression of the activation of Ca2`-sensitive K+ channels, while the action of the drug on other K+ channels, presumably the ATP-sensitive K+ channels (Sturgess et al., 1985; Trube et al., 1986) , still persists. It should be emphasized, however, that the observed changes in 'Rb efflux are only tentatively ascribed to specific types of K+ channels. Since no pharmacological blocker is sufficiently specific of one type of K+ channel, single channel studies by the patch clamp technique will be necessary to verify the validity ofour interpretation. Very little is known about the stereoselectivity of hypoglycaemic substances. More than 20 years ago, studies on the metabolites of the sulphonylurea acetohexamide revealed that the (-)-enantiomer of hydroxyhexamide was 2.4 times more potent than the racemic mixture in inducing hypoglycaemia in the rat (McMahon et al., 1965) . Stereoselectivity has also been described for sulphonamides of the second generation possessing an asymmetric C atom directly attached to the N atom of the amide group present in their nonsulphonylurea moiety (Rufer et al. 1974) , as well as for the benzoic acid derivative corresponding to that nonsulphonylurea moiety (Rufer & Losert, 1979) . For all tested compounds, the hypoglycaemic activity of the (S)-enantiomer was 20-100 times greater than that of the (R)-enantiomer. A ratio of about 15 characterizes the hypoglycaemic potency of the two enantiomers of AZ-DF 265 (E. Rupprecht, personal communication). Such in vivo studies did not identify the site(s) of the stereoselectivity. The present work is, to our knowledge, the first to demonstrate stereoselective stimulation of insulin release in vitro by a pharmacological agent of potential clinical usefulness. The potency of (-)-AZ-DF 265 was 10 times higher than that of (+)-AZ-DF 265. This ratio, similar to that found in vivo, is likely to be underestimated because of the small contamination of the (+ )-enantiomer by the more potent (-)-enantiomer of AZ-DF 265. Most interestingly, this stereoselectivity also characterized the effect of the drug on IRb efflux. This lends further support to the above conclusion that the change in K+ permeability of the P-cell membrane is critically involved in the stimulation of insulin release. This also suggests that blockade ofK+ channels does not merely result from accumulation of the drug in the membrane but involves a much more specific interaction with a reactive site (NH-CO?) in the molecule.
In conclusion, stimulation of insulin release with a very high potency can be achieved by a pharmacological agent that is not a sulphonamide. A sulphonylurea group should no longer be regarded as the optimal chemical function for an interaction with pancreatic a-cells. Pharmacokinetic studies will be necessary to ascertain whether benzoic acid derivatives such as AZ-DF 265 have clinical advantages over currently available drugs. Their stereoselectivity, however, makes them interesting tools to gain insight into the mechanisms of K+ channel blockade, in particular to determine whether this blockade results from the interaction ofvarious chemical groups with a single binding site ofrelatively low specificity or with distinct binding sites. It may also help disclose differences between K+ channels in P-cells and other tissues (in particular heart cells). One may hope that this new information will lead to the synthesis of the optimal drug aimed at stimulating insulin release.
